310 related articles for article (PubMed ID: 11929787)
41. Targeting of the N-terminal coiled coil oligomerization interface of BCR interferes with the transformation potential of BCR-ABL and increases sensitivity to STI571.
Beissert T; Puccetti E; Bianchini A; Güller S; Boehrer S; Hoelzer D; Ottmann OG; Nervi C; Ruthardt M
Blood; 2003 Oct; 102(8):2985-93. PubMed ID: 12829585
[TBL] [Abstract][Full Text] [Related]
42. Examination of clinically-derived p210 BCR/ABL1 RhoGEF mutations in a murine bone marrow transplantation model of CML.
Ciccarelli BT; Hu T; Wang Q; Kim JJ; Whitehead IP
Leuk Res; 2020 Oct; 97():106440. PubMed ID: 32892149
[TBL] [Abstract][Full Text] [Related]
43. BCR-ABL activates STAT3 via JAK and MEK pathways in human cells.
Coppo P; Flamant S; De Mas V; Jarrier P; Guillier M; Bonnet ML; Lacout C; Guilhot F; Vainchenker W; Turhan AG
Br J Haematol; 2006 Jul; 134(2):171-9. PubMed ID: 16846476
[TBL] [Abstract][Full Text] [Related]
44. Targeting BCR tyrosine177 site with novel SH2-DED causes selective leukemia cell death in vitro and in vivo.
Peng Z; Yuan Y; Li YJ; Wang HX; Shi J; Cao WX; Luo HW; Deng JR; Feng WL
Int J Biochem Cell Biol; 2012 Jun; 44(6):861-8. PubMed ID: 22349215
[TBL] [Abstract][Full Text] [Related]
45. Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR/ABL.
Sattler M; Salgia R
Cytokine Growth Factor Rev; 1997 Mar; 8(1):63-79. PubMed ID: 9174663
[TBL] [Abstract][Full Text] [Related]
46. Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway.
Puil L; Liu J; Gish G; Mbamalu G; Bowtell D; Pelicci PG; Arlinghaus R; Pawson T
EMBO J; 1994 Feb; 13(4):764-73. PubMed ID: 8112292
[TBL] [Abstract][Full Text] [Related]
47. [Overexpression of Shp-2 is associated with the unlimited growth and apoptosis resistance of p210 bcr-abl-mediated chronic myeloid leukemia].
Zhu XZ; Yu YZ; Fang YM; Liang Y; Lü QH; Xu RZ
Zhonghua Yi Xue Za Zhi; 2005 Jul; 85(27):1903-6. PubMed ID: 16255985
[TBL] [Abstract][Full Text] [Related]
48. Bcr: a negative regulator of the Bcr-Abl oncoprotein in leukemia.
Arlinghaus RB
Oncogene; 2002 Dec; 21(56):8560-7. PubMed ID: 12476302
[TBL] [Abstract][Full Text] [Related]
49. BCR-ABL-induced adhesion defects are tyrosine kinase-independent.
Wertheim JA; Forsythe K; Druker BJ; Hammer D; Boettiger D; Pear WS
Blood; 2002 Jun; 99(11):4122-30. PubMed ID: 12010816
[TBL] [Abstract][Full Text] [Related]
50. BCR-tyrosine 177 plays an essential role in Ras and Akt activation and in human hematopoietic progenitor transformation in chronic myelogenous leukemia.
Chu S; Li L; Singh H; Bhatia R
Cancer Res; 2007 Jul; 67(14):7045-53. PubMed ID: 17638918
[TBL] [Abstract][Full Text] [Related]
51. The function of BCR/ABL and related proto-oncogenes.
Gotoh A; Broxmeyer HE
Curr Opin Hematol; 1997 Jan; 4(1):3-11. PubMed ID: 9050373
[TBL] [Abstract][Full Text] [Related]
52. Molecular biology of chronic myeloid leukemia.
Maru Y
Int J Hematol; 2001 Apr; 73(3):308-22. PubMed ID: 11345196
[TBL] [Abstract][Full Text] [Related]
53. Localization of BCR-ABL to F-actin regulates cell adhesion but does not attenuate CML development.
Wertheim JA; Perera SA; Hammer DA; Ren R; Boettiger D; Pear WS
Blood; 2003 Sep; 102(6):2220-8. PubMed ID: 12791659
[TBL] [Abstract][Full Text] [Related]
54. Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis.
Cortez D; Kadlec L; Pendergast AM
Mol Cell Biol; 1995 Oct; 15(10):5531-41. PubMed ID: 7565705
[TBL] [Abstract][Full Text] [Related]
55. Requirement of c-Myb for p210(BCR/ABL)-dependent transformation of hematopoietic progenitors and leukemogenesis.
Lidonnici MR; Corradini F; Waldron T; Bender TP; Calabretta B
Blood; 2008 May; 111(9):4771-9. PubMed ID: 18227349
[TBL] [Abstract][Full Text] [Related]
56. BCR/ABL-mediated increased expression of multiple known and novel genes that may contribute to the pathogenesis of chronic myelogenous leukemia.
Salesse S; Verfaillie CM
Mol Cancer Ther; 2003 Feb; 2(2):173-82. PubMed ID: 12589034
[TBL] [Abstract][Full Text] [Related]
57. Ubiquitin-mediated interaction of p210 BCR/ABL with β-catenin supports disease progression in a murine model for chronic myelogenous leukemia.
Chen R; Hu T; Mahon GM; Tala I; Pannucci NL; Ozer HL; Whitehead IP
Blood; 2013 Sep; 122(12):2114-24. PubMed ID: 23950177
[TBL] [Abstract][Full Text] [Related]
58. Expression of the ABL-BCR fusion gene in Philadelphia-positive acute lymphoblastic leukemia.
Melo JV; Gordon DE; Tuszynski A; Dhut S; Young BD; Goldman JM
Blood; 1993 May; 81(10):2488-91. PubMed ID: 8490164
[TBL] [Abstract][Full Text] [Related]
59. Peptide containing the BCR oligomerization domain (AA 1-160) reverses the transformed phenotype of p210bcr-abl positive 32D myeloid leukemia cells.
Guo XY; Cuillerot JM; Wang T; Wu Y; Arlinghaus R; Claxton D; Bachier C; Greenberger J; Colombowala I; Deisseroth AB
Oncogene; 1998 Aug; 17(7):825-33. PubMed ID: 9779999
[TBL] [Abstract][Full Text] [Related]
60. A coiled-coil tetramerization domain of BCR-ABL is essential for the interactions of SH2-containing signal transduction molecules.
Tauchi T; Miyazawa K; Feng GS; Broxmeyer HE; Toyama K
J Biol Chem; 1997 Jan; 272(2):1389-94. PubMed ID: 8995449
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]